Engflag

Lan - 30

Quick links to important sections

Lan - 30

Lan - 30_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lan - 30

Quick Facts

Property Description
Active ingredient Lansoprazole
Form Capsule (with enteric-coated granules)
Pharmacological class Proton Pump Inhibitor (PPI)
Common use Mitigation of acid-related discomfort
Origin Synthetic (Substituted Benzimidazole)

What is Lan-30?

Lan-30 is a pharmaceutical preparation whose core purpose is to significantly and reliably reduce the amount of acid produced by the stomach. It is a prescription-only medication that falls within the class of powerful acid-suppressing agents.

What Type of Medicine is Lan-30?

Lan-30 is a synthetic, single-ingredient medicine classified pharmacologically as a Proton Pump Inhibitor (PPI). The active substance responsible for its action is Lansoprazole, a substituted benzimidazole compound. The PPI class is recognized for providing more sustained acid control than traditional H2-blockers. This classification indicates that the medicine provides a durable reduction in overall stomach acidity.

Composition and Form of the Lan-30 Capsule

Lan-30 is manufactured as a standard capsule intended for oral administration. The capsule contains the active ingredient, Lansoprazole, formulated as tiny, protected enteric-coated granules. This specific design is vital because Lansoprazole is sensitive to the acidic environment of the stomach and would be rapidly inactivated otherwise. The enteric coating acts as a shield, ensuring the drug passes safely into the small intestine where it can be absorbed effectively. The 30 mg strength, indicated by the "30" in the name, is a standardized dosage strength developed for its robust acid-suppressing effect.

What is the General Purpose of Lansoprazole?

The general purpose of Lansoprazole is to mitigate the effects of excessive stomach acid by irreversibly inhibiting the dedicated proton pumps in the stomach lining. By effectively shutting down these pumps, the medicine dramatically lowers the overall level of acidity in the stomach. This foundational action is applied in situations requiring acid suppression, such as providing relief and healing support for acid indigestion and severe heartburn episodes.

Regulatory References

  1. National Library of Medicine

What side effects are possible with Lan - 30?

Possible Side Effects and Safety Information

The official safety profile for Lan-30 (Lansoprazole) details potential adverse reactions classified by their frequency and the body system affected, according to regulatory documents from the FDA and EMA. Adverse reactions are grouped across multiple System Organ Classes, including Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized from Common (reported in 1/10 to 1/100 patients) to Rare (reported in 1/1,000 to 1/10,000 patients).

Common effects typically documented in official labeling include headache, dizziness, diarrhea, abdominal pain, nausea, and vomiting.

Serious Adverse Reactions

The regulatory label documents rare but clinically significant adverse reactions. These include severe immune or cutaneous reactions such as Anaphylactic shock, Stevens-Johnson syndrome (SJS), and Toxic Epidermal Necrolysis (TEN). Acute kidney injury, specifically Acute Tubulointerstitial Nephritis (TIN), has also been documented in post-marketing reports.

Duration- and Population-Related Safety Notes

The official safety information notes specific risks associated with the duration of use. Long-term therapy (one year or longer) is linked to an increased risk of osteoporosis-related fractures (hip, wrist, or spine) and deficiencies such as Hypomagnesaemia and Vitamin B12 deficiency. The medicine requires particular safety supervision in patients with severe hepatic impairment, and use is not recommended for children below one year of age. The safety constraints also note that symptomatic improvement does not rule out the presence of gastric malignancy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Lan-30 overdose indicates that clinical experience with acute ingestion is limited. In one documented instance involving a massive ingestion up to 600 mg, which is significantly higher than the typical prescribed daily dose, no clinically significant adverse events or acute symptoms were reported as a direct result of the overdose. Consequently, the official prescribing information does not define a specific dose amount associated with severe toxicity or list a detailed acute symptom profile.

Required Emergency Actions

Regulatory authorities uniformly mandate that individuals must seek immediate emergency medical attention for any suspected overdose scenario. This action is necessary regardless of whether the individual is currently experiencing symptoms or has ingested a known massive dose. Patients are further directed to contact a certified Poison Control Center for specialized guidance and necessary next steps.

Overdose Management

There is no specific antidote known for Lan-30, which means the effects cannot be pharmacologically reversed. Therefore, the official management strategy is focused on providing symptomatic and supportive treatment. Procedural interventions to limit systemic absorption, such as gastric emptying or the use of activated charcoal, may be considered by healthcare professionals where clinically warranted based on the severity and context of the exposure.

Therapeutic Uses of Lan - 30

Quick Facts: Therapeutic Uses

  • Conditions Addressed: Management of active duodenal ulcers, gastric ulcers, and erosive esophagitis.
  • Symptom Management: Relief of symptoms associated with gastroesophageal reflux disease (GERD).
  • Risk Reduction: Used for decreasing the risk of recurrence of duodenal ulcers.
  • Specific Conditions: Management of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.

Lan-30 is a prescribed medication utilized in the therapeutic management of conditions involving elevated stomach acid levels. It is employed for the short-term treatment and healing of active duodenal ulcers and active benign gastric ulcers. The agent is also indicated for the maintenance of healed duodenal ulcers, contributing to the reduction of recurrence risk.

For conditions related to acid reflux, Lan-30 is used in the short-term treatment of both symptomatic gastroesophageal reflux disease (GERD) and erosive esophagitis (EE). Furthermore, it is used for the long-term management of pathological hypersecretory states, such as Zollinger-Ellison Syndrome.

The medication may be used as part of a combination regimen for the eradication of H. pylori bacteria in patients diagnosed with H. pylori associated ulcers, with the goal of reducing duodenal ulcer recurrence.

Eligibility and Restrictions for Use

Who can and cannot use Lan-30?

Eligibility to use Lan-30 (lansoprazole) is strictly defined by regulatory authorities based on population age, physiological state, and co-administration with other medicines. This information is derived from official government prescribing documents.

Contraindications and Prohibited Use

Lan-30 is contraindicated and must not be used if you have a known hypersensitivity or allergy to lansoprazole or any of the inactive ingredients. Use is also prohibited for patients concurrently taking rilpivirine-containing products or pH-dependent atazanavir, as this can significantly reduce the effectiveness of those HIV medications.

Age and Condition-Based Restrictions

Population Category Eligibility Status (Official Labeling)
Approved Age Adults and pediatric patients 1 year of age and older
Infants (< 1 year) Use is not recommended; safety and efficacy are not established
Severe Hepatic Impairment Requires caution; lower daily doses may be necessary
Renal Impairment Use is allowed; no dose adjustment is required

Use in pregnancy is generally restricted to when it is clearly needed. Lan-30 is not recommended for nursing mothers due to the presence of the drug in animal milk.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section summarizes the clinically significant drug-drug and drug-product interactions for Lansoprazole (Lan-30) as documented in official regulatory labeling.

Lansoprazole's primary interaction mechanism involves its effect on gastric pH. By increasing stomach pH, it can alter the absorption of co-administered medicines, particularly those whose bioavailability is dependent on an acidic environment (e.g., ketoconazole, atazanavir, and digoxin). Reduced absorption may decrease the effectiveness of these drugs, while increased absorption can raise systemic levels of others, such as Digoxin.

A second interaction mechanism is metabolic. Lansoprazole is a substrate and inhibitor of the CYP2C19 enzyme. Co-administration with sensitive CYP2C19 substrates, such as methotrexate, can increase the substrate's plasma concentrations, requiring careful monitoring.

Documented Interaction Requirements

Classification Interacting Product(s) Requirement/Constraint
Contraindicated Rilpivirine-containing products Must not be co-administered due to loss of antiviral efficacy.
Timing Separation Sucralfate Must be taken at least 30 minutes after Lansoprazole.
Exposure Monitoring Methotrexate, Digoxin Requires clinical and/or laboratory monitoring.
Food Constraint Food Administration should occur before a meal for optimal bioavailability.

Population-Specific Note: Official labeling indicates that patients with severe hepatic impairment may require caution due to potential changes in Lansoprazole metabolism, which could affect the severity of interactions with co-administered drugs.

Mechanism of Action

How Lan-30 Works: Mechanism of Action

The action of Lansoprazole (Lan-30) is mediated by the irreversible inhibition of the H^+/K^+-ATPase enzyme, commonly known as the Proton Pump, found exclusively in the gastric parietal cells. The molecule functions as an acid-activated prodrug, concentrating in the low pH environment of the secretory canaliculus where it is chemically transformed into its active sulfonamide metabolite. This metabolite forms a stable covalent bond with the enzyme, effectively locking the pump in an inactive state. This molecular interaction halts the active transport of hydrogen ions ( H^+) into the stomach lumen, thereby blocking the Final Common Pathway of Acid Secretion irrespective of upstream stimuli like histamine or gastrin. The resulting pathway suppression causes a sustained elevation of the gastric pH. The duration of this physiological effect is determined by the rate of new enzyme synthesis (turnover) by the parietal cell, as the cessation of proton transport persists until new, unblocked pumps replace the inhibited ones.

Dosage and Administration Information

How to Use Lan - 30 (Lansoprazole)

The administration of Lan-30 is governed by specific procedural requirements designed to protect the enteric-coated granules from stomach acid, ensuring the active ingredient reaches the small intestine for absorption.

Administration Scope

Feature Guideline
Route of administration Oral (swallowing the whole capsule) or via Nasogastric (NG) tube (using intact granules).
Dosing schedule 30 mg once daily is the standard regimen for healing in many scenarios, while 30 mg twice daily is used in combination therapies, such as H. pylori eradication.
Timing in relation to meals Must be taken at least 30 minutes before food.
Preparation requirements The capsule must not be crushed, chewed, or ground. Intact granules can be mixed with approved soft foods or acidic juices for immediate oral administration. For NG tubes, granules are mixed with 40 mL of apple juice only.
Age-group administration rules The daily dose for older adults should generally not exceed 30 mg. A 50% dose reduction is recommended for patients with moderate to severe hepatic impairment. No adjustment is needed for renal impairment.
Missed-dose rules Patients are instructed not to take two doses at one time to compensate for a forgotten dose.
Special procedural conditions The capsule or its enteric-coated granules must not be crushed, chewed, or ground.

Connection to the overall use protocol

The official use protocol is structured around preserving the integrity of the delayed-release formulation and ensuring administration occurs on an empty stomach. This mandated handling (no crushing) and strict pre-meal timing are procedural requirements designed to ensure the drug reaches the small intestine for absorption. The regimen is defined by specific dosage tiers and defined treatment lengths (e.g., 4 or 8 weeks) established for each approved application.

Recent Clinical Evidence

Research evidence / Overview of studies for Lan - 30

Evidence for Healing and Maintenance of Esophageal Erosion

Research involving Lansoprazole (Lan-30) includes short-term, controlled clinical trials conducted in populations presenting with acid-related conditions. These studies primarily examine endpoints related to mucosal changes in erosive esophagitis (EE). The evidence base consists of Randomized Controlled Trials (RCTs), where researchers monitored outcomes such as the rate of mucosal healing, measured using endoscopy. Studies reported observations of the proportions of patients reaching a defined endoscopic endpoint within the typical 4- to 8-week period.

For patients who met the criteria for initial mucosal healing, separate long-term trials were conducted to evaluate the maintenance phase. These trials were designed to observe the durability of the initial mucosal status and to measure the recurrence of breaks over periods up to one year. Controlled studies described the observed rates of mucosal integrity maintenance throughout the year, but very long-term outcomes are not well characterized, as evidence often relies on less controlled, open-label designs.

Research on Peptic Ulcer Healing and H. Pylori Regimens

Lansoprazole was studied in research examining measurable changes in peptic ulcers, including gastric and duodenal, as well as those associated with the chronic use of NSAIDs. Findings describe the measured rates of ulcer closure, confirmed by endoscopy. A significant portion of this evidence was generated before standardized protocols for H. pylori infection were widely adopted.

Lansoprazole was also observed in studies as part of a multi-drug combination regimen intended to achieve eradication of the H. pylori bacteria. Data show patterns related to how measured clearance rates were associated with the specific antibiotics used alongside Lansoprazole. Findings were observed in some studies to vary, as clearance is known to be affected by regional antibiotic resistance patterns.

Extended-Duration and Specific Population Data

Research examined extended duration protocols in patients with conditions characterized by fluctuating manifestations. Long-term studies monitored outcomes related to the durability of a therapeutic response. Limited information is available regarding outcomes following discontinuation of maintenance therapy after extended use.

Lansoprazole was observed in studies for use in specific populations beyond adult groups. Research has examined measured outcomes in adolescents (ages 12–17) and, through Pharmacokinetic/Pharmacodynamic (PK/PD) studies, in children (ages 1–11). The evidence describing research findings in the youngest pediatric populations is often limited, and information regarding these populations is sometimes informed by extrapolation from adult PK/PD data rather than dedicated, large-scale studies evaluating research findings.

Key Studies & References

  1. Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori (Discusses regional resistance variability)
  2. Comparative effectiveness of different recommended doses of omeprazole and lansoprazole for gastroesophageal reflux disease (GERD)

Frequently Asked Questions (FAQ)

Common questions about Lan - 30 (FAQ)

Q: How quickly does Lan - 30 typically start working or show initial effects?

Initial relief of symptoms may occur soon after starting the medicine, but official product information indicates that the full therapeutic effect for comprehensive symptom relief may take between one to four days. The medicine is generally not intended for immediate, on-demand relief.

Q: What is the average time it takes to see the full effect of Lan - 30?

The full therapeutic effect for symptom relief may take a few days. Furthermore, defined treatment courses for the healing of conditions like erosive esophagitis (severe heartburn) are typically defined by regulatory authorities for a period of four to eight weeks to achieve mucosal healing.

Q: Does the risk of a severe side effect go up the longer a person takes Lan - 30?

Official safety information describes that long-term therapy (use for one year or longer) is associated with an elevated occurrence of specific conditions. These include osteoporosis-related fractures (hip, wrist, or spine) and deficiencies of Vitamin B12 and the mineral magnesium.

Q: Is it common for doctors to adjust the dose of Lan - 30 over time?

Official information describes specific circumstances where dosage may require adjustment. For example, a lower dose may be necessary for patients with severe hepatic (liver) impairment, or for older adults, where the official prescribing information states the daily dose should not typically exceed 30 mg.

Q: Is Lan - 30 safe to use while breastfeeding?

Official regulatory labeling indicates that the use of this medicine is not recommended for nursing mothers. Regulatory information indicates that the decision to discontinue the medicine or discontinue breastfeeding requires the judgment of a healthcare provider.

Q: What is the maximum duration of time Lan - 30 is typically prescribed for?

The recommended treatment length is defined by the condition being addressed. For many acute conditions, such as treating active ulcers or severe inflammation of the esophagus, the standard prescription duration is typically defined for a specific period, often lasting four to eight weeks.

Q: Are there any reported issues with Lan - 30 and fertility?

Official labeling addresses potential effects on fertility, as required by regulatory bodies. Research in animals has generally not indicated specific harm to fertility. Specific human data on this topic is often limited or not readily available.

Q: Can Lan - 30 affect the results of certain lab tests?

Yes, official documents contain information regarding the medicine's potential interaction with specific laboratory investigations. This is particularly noted for certain specialized tests, such as the Chromogranin A (CgA) test, which is sometimes used to investigate neuroendocrine tumors.

Q: Is Lan - 30 a cure or a treatment for the condition it is prescribed for?

Lan-30 is classified as a medicine intended for the treatment of conditions caused by excessive stomach acid. Its purpose is to support the healing of ulcers and esophagitis and to assist in the maintenance of a healed state by significantly reducing acid production.

Q: Are there any long-term effects described in official research for Lan - 30?

Long-term use (one year or longer) is associated with an increased occurrence of specific conditions, as noted in the safety warnings. These include osteoporosis-related fractures of the hip, wrist, or spine, and deficiencies of the mineral magnesium and Vitamin B12.

Q: Is Lan - 30 known to be addictive or habit-forming?

Lan-30 (Lansoprazole) is a pharmaceutical medicine that is not classified as a federally controlled substance.

Q: How does Lan - 30 compare to other older medicines used for the same condition?

Lan-30 belongs to the Proton Pump Inhibitor (PPI) class of medicines. This class is pharmacologically recognized for achieving a more significant and sustained reduction in stomach acid levels than an older class of drugs called H2-receptor antagonists (H2-blockers).

Q: What should a patient do if they notice an unusual side effect not listed in the leaflet?

Official patient information describes that immediate medical attention is necessary if severe or unusual symptoms occur. This includes signs of severe immune or skin reactions (like blistering rashes) or symptoms of acute kidney injury.

Q: Does Lan - 30 interact with common over-the-counter pain relievers or cold medicines?

The official label instructs patients to inform their healthcare provider about all medicines they are taking, including over-the-counter (OTC) drugs and supplements. This is because these products, particularly certain herbal items, may affect how Lan-30 works.

Q: Can herbal supplements or vitamins affect how Lan - 30 works?

Official product information emphasizes that patients should inform their healthcare provider about the use of all vitamins, minerals, and herbal supplements. These products can potentially affect the medicine's activity or absorption.

Q: Is it true that Lan - 30 can cause weight changes?

Weight changes are not listed as a common or frequent side effect in the primary safety profile. However, official safety data does include less frequent events such as changes in appetite and localized reactions like edema (swelling), which could potentially influence body weight.

Q: What happens if I stop taking Lan - 30 suddenly?

Official documents do not generally specify outcomes for sudden cessation. However, research observes that upon discontinuation of acid suppression therapy, a temporary increase in stomach acid production, known as rebound hypersecretion, may occur.

Q: Does Lan - 30 affect a person's ability to drive or operate machinery?

Official safety information lists potential side effects related to the nervous system, such as dizziness and tiredness. If a person experiences these effects, their ability to drive or operate machinery may be affected, according to warnings.

Q: Is there a link between Lan - 30 and increased feelings of anxiety or depression?

The official list of potential adverse reactions does include effects classified under nervous system disorders. These infrequent reactions include descriptions such as anxiety and nervousness.

Q: Can a patient be allergic to Lan - 30, and what are the signs?

Lan-30 is contraindicated (prohibited for use) if a known hypersensitivity or allergy to the medicine or its inactive ingredients exists. Signs of a severe allergic reaction can include a rash, blisters, swelling of the face, or difficulty breathing.

Q: Does Lan - 30 have any known interactions with alcohol?

The official labeling indicates that it is unknown if consuming alcohol specifically affects how the medicine works. However, general guidance for acid-related conditions often suggests that patients avoid the consumption of alcohol, as it can stimulate acid production.

Q: Does the medication need to be stored in a special way (e.g., refrigerated)?

The official label requires the medicine to be stored at controlled room temperature, typically below 30 C or 86 F. It must also be protected from moisture and direct light. Refrigeration is not an approved storage condition for the capsule.

Q: Is Lan - 30 a controlled substance in my region?

Lan-30 (Lansoprazole) is not classified as a federally controlled substance in the United States.

Q: What are the main risk factors for having an adverse reaction to Lan - 30?

Official warnings highlight certain patient circumstances that may be associated with increased risk. These include a known hypersensitivity to the drug, having severe hepatic (liver) impairment, or engaging in long-term use (for specific risks like fracture and nutrient deficiency).

Q: How does Lan - 30 affect a person's sleep patterns?

The list of potential side effects includes effects related to the central nervous system, such as headache and dizziness. While specific disturbances of sleep patterns are not a commonly listed side effect, these central nervous system effects may indirectly affect rest.

Q: Can exposure to sunlight be an issue while taking Lan - 30?

Yes, increased sensitivity to sunlight (known as photosensitivity) is listed in the official safety information as a possible side effect of Lan-30.

Q: Are there any lifestyle changes mentioned in the official documents that support Lan - 30 treatment?

General non-directive patient information often suggests that avoiding foods and drinks that trigger acid discomfort (such as rich/spicy foods or alcohol) and adjusting eating habits (e.g., not eating before bed) may support the overall treatment plan.

Q: Are there any known genetic factors that impact the response to Lan - 30?

Regulatory-associated guidance describes how variations in the CYP2C19 enzyme gene can affect how a person's body processes Lan-30. This processing difference can influence both the drug's effectiveness and the concentration of the medicine in the blood.

Q: Is it possible to have an interaction between Lan - 30 and caffeine?

Official non-directive information often suggests that patients avoid the consumption of caffeine, as it is known to be an acidic or stimulating product that can promote acid production in the stomach.

Q: Can taking Lan - 30 lead to vitamin or mineral deficiencies?

Official safety information indicates that prolonged use (one year or longer) is associated with potential deficiencies. These include the mineral magnesium (Hypomagnesaemia) and Vitamin B12.

How should Lan - 30 be stored and disposed of?

How to Store and Dispose of Lan-30

Official regulatory guidelines dictate specific environmental and containment rules for the storage and disposal of Lan-30 (Lansoprazole) capsules.

Storage Requirement Official Classification
Temperature Store at controlled room temperature, typically below 30 C (86 F), or between 20 C and 25 C.
Protection Must be protected from moisture and direct light.
Container Rule Keep the capsules in the original, tightly closed container (or blister pack).
Stability If supplied in a bottle, the shelf-life after the container is first opened may be limited to three months (90 days).

All packaging must be stored out of the sight and reach of children. Unused or expired Lan-30 should be disposed of via an authorized drug take-back program. If a take-back option is unavailable, the capsules should be mixed with an unappealing substance (like dirt or used coffee grounds) and sealed in a bag before placing in household trash. Do not flush the medicine down the toilet or sink, and follow all local environmental regulations for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lan - 30 found in:

A-Z Index: